Supporting Data Release Notes – 4.60

December 13, 2024

# Overview

This release notes document provides a high-level list of changes. More specific details can be found inside supporting data spreadsheets in the Change History tab.

# Structural Changes

* The AntigenSupportingData.xsd was improved to support XML validation. The definition for the preferableVaccine element was updated to include minOccurs=”0” for each element within preferableVaccine (e.g., vaccineType, cvx, beginAge, etc.). Depending upon the XML validator being used, this was previously throwing a validation error.
  + Before: <xs:element type="xs:string" name="vaccineType"/>
  + After: <xs:element type="xs:string" name="vaccineType" minOccurs="0"/>

# Schedule Supporting Data Changes

Table 1: Schedule Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| Live Virus Conflicts | * Added support for Chikungunya vaccine (CVX 317) |
| Coded Observations | * Added contraindication text to observation codes 010 and 011 |

# Antigen Series Supporting Data Changes

Table 2: Antigen Series Specific Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| COVID-19 | * Updates to support an additional dose in 6 months for all persons with moderate-to-severe immunocompromise or all persons 65 years of age and older. * Updates to support additional doses every 2 months for all persons with moderate-to-severe immunocompromise * Minor preferable vaccine adjustments in mRNA-specific series for those under 5 years of age to better support interchangeability once the primary series has been completed. * New skip conditions in the Pfizer and Moderna specific 6 mo – 4 yr series to accommodate the note for those transition from 4 to 5 years and at least 8 weeks removed from their previous dose. This note allows these patients to receive any mRNA vaccine. * Additional skip on dose 3 in the 6 mo – 4 yr Mixed Product series to support inadvertent Novavax administration guidance. * Miscellaneous technical corrections discovered during quality assurance reviews. |
| Dengue | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Influenza | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Measles | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Meningococcal ACWY | * Removed CVX 32 (Mening MPSV4) as an allowable vaccine on dose 1 of the 2-dose age-based series per SME guidance. |
| Mumps | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Pneumococcal | * Updated the absolute minimum age on dose 1 of the 50+ 2-dose PPSV23-PCV series |
| Rubella | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Varicella | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |
| Yellow Fever | * Typo correction in the Contraindications tab for observation code 157 (solid organ transplantation) |